🔴 Gossamer Bio is trading 5.5% down today as FDA has yet to accept seralutinib filing

Gossamer Bio is trading 5.5% down now at $10.33 as investors reassess the September 23, 2026 FDA submission for seralutinib.

• The application follows PROSERA results, where walking-distance improvement missed its preset statistical cutoff.
• The FDA has not yet accepted the filing for review, leaving regulatory uncertainty around the submission.
• The stock recently fell 10.13% on September 18 and 5.99% on September 23.